Mammo breast cancer

Boehringer Ingelheim has reported positive results from two trials evaluating afatinib in the treatment of patients with breast cancer.

The Phase III LUX-Breast 1 trial compared afatinib plus vinorelbine (experimental arm) with trastuzumab plus vinorelbine in patients with HER2-positive metastatic breast cancer after failure of prior trastuzumab-based therapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial showed similar progression-free survival and objective response in both treatment arms, but shorter overall survival in the experimental arm.

Diarrhoea, neutropenia and rash were the most common adverse events observed with afatinib plus vinorelbine, while neutropenia, leukopenia and anaemia were reported with trastuzumab plus vinorelbine.

The company said that the combination of afatinib plus vinorelbine was less tolerable with a higher rate of dose reductions and treatment discontinuations compared to trastuzumab plus vinorelbine.

Patient enrolment in the trial was closed in April 2013, following the recommendation of the independent Data Monitoring Committee (DMC).

Based on the results, the company discontinued recruitment into all trials investigating afatinib plus vinorelbine in HER2-positive metastatic breast cancer.

LUX-Breast 3 is a randomised, open-label Phase II trial in patients with HER2-positive breast cancer progressing with brain metastases.

The three-armed trial compared afatinib, afatinib plus vinorelbine and investigator’s choice of therapy, after prior trastuzumab and/or lapatinib-based therapy.

Results from LUX-Breast 3, showed no benefit for afatinib-containing regimens over treatments selected by the physician as measured by the primary endpoint of patient benefit at 12 weeks and secondary endpoints including progression-free survival and overall survival.

The results from these two trials were presented at the 2014 San Antonio Breast Cancer Symposium (SABCS).

In the EU, Japan, Taiwan and Canada afatinib is approved under the brand name GIOTRIF, while in the US it is approved under the brand name GILOTRIF for use in patients with distinct types of EGFR mutation-positive non-small cell lung cancer (NSCLC).

The approval of afatinib to treat distinct types of EGFR mutation-positive NSCLC was based on the results of LUX-Lung 3 trial, which is part of the LUX-Lung clinical trial programme.

The trial met its primary end point of progression-free survival and showed that afatinib significantly delayed tumour growth when compared to standard chemotherapy.

Image: Mammograms showing a normal breast (left) and a cancerous breast (right). Photo: courtesy of Morning2k.